1. Home
  2. FEBO vs MBAI Comparison

FEBO vs MBAI Comparison

Compare FEBO & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

HOLD

Current Price

$1.16

Market Cap

11.8M

Sector

N/A

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.68

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FEBO
MBAI
Founded
1993
2004
Country
Hong Kong
Israel
Employees
N/A
85
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
12.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
FEBO
MBAI
Price
$1.16
$1.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.8K
45.9K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$1.31
52 Week High
$1.48
$3.92

Technical Indicators

Market Signals
Indicator
FEBO
MBAI
Relative Strength Index (RSI) 48.51 49.45
Support Level $1.08 $1.38
Resistance Level $1.16 $1.89
Average True Range (ATR) 0.09 0.15
MACD 0.00 0.00
Stochastic Oscillator 16.67 28.17

Price Performance

Historical Comparison
FEBO
MBAI

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: